Item 2.02. Results of Operations and Financial Condition. On May 6, 2021, NGM Biopharmaceuticals, Inc. provided business highlights and reported its financial results for the first quarter ended March 31, 2021. A copy of the press release titled "NGM Bio Provides Business Highlights and Reports First Quarter 2021 Financial Results," is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto and is incorporated herein by reference. Item 9.01 Financial Statements and Exhibits. (d) Exhibits


    Exhibit No.                                           Description

99.1                          Press release, dated     May     6    , 2021, titled "NGM Bio Provides
                            Business Highlights and Reports     First     Quarter     2021
                              Financial Results."

The information in this report, including the exhibit hereto, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by NGM Biopharmaceuticals, Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses